{"id":617,"date":"2026-03-24T07:40:11","date_gmt":"2026-03-24T14:40:11","guid":{"rendered":"https:\/\/www.leapfrog.bio\/?p=617"},"modified":"2026-10-19T12:21:37","modified_gmt":"2026-10-19T19:21:37","slug":"leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board","status":"publish","type":"post","link":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","title":{"rendered":"Leapfrog Bio nomme Alan Ashworth, Ph.D., FRS, comme pr\u00e9sident de son conseil consultatif scientifique"},"content":{"rendered":"

\u2014Le Dr Ashworth apporte des d\u00e9cennies d'exp\u00e9rience scientifique et clinique pour traduire les d\u00e9couvertes sur la l\u00e9talit\u00e9 synth\u00e9tique en
th\u00e9rapies anticanc\u00e9reuses de pr\u00e9cision \u2014<\/p>\n

\n

South San Francisco (Californie), le 24 mars 2026 <\/b>(Lire sur GlobeNewswire<\/a><\/u><\/span><\/span>)<\/span> \u2014<\/b> <\/span>Leapfrog Bio, a clinical-stage precision oncology company dedicated to discovering and developing novel targeted therapies for cancers caused by loss-of-function (LOF) mutations, today announced the appointment of Alan Ashworth, Ph.D., FRS, to chair the company\u2019s Scientific Advisory Board.<\/p>\n

Le Dr Ashworth est un expert de renomm\u00e9e mondiale en recherche sur le cancer et un chef de file international dans le d\u00e9veloppement de th\u00e9rapies oncologiques. Il a jou\u00e9 un r\u00f4le d\u00e9terminant dans l\u2019identification du g\u00e8ne BRCA2 et a contribu\u00e9 \u00e0 \u00e9tablir son r\u00f4le dans la r\u00e9paration de l\u2019ADN et la recombinaison homologue \u2014 des travaux qui ont ouvert la voie \u00e0 l\u2019inhibition de PARP comme strat\u00e9gie th\u00e9rapeutique.\n\nLa d\u00e9couverte, par son \u00e9quipe, de la relation de l\u00e9talit\u00e9 synth\u00e9tique entre BRCA1\/2 et les inhibiteurs de PARP a orient\u00e9 le d\u00e9veloppement de l\u2019olaparib, premier inhibiteur de PARP cibl\u00e9 sur le plan g\u00e9n\u00e9tique \u00e0 avoir \u00e9t\u00e9 approuv\u00e9, constituant une validation clinique majeure de l\u2019approche de l\u00e9talit\u00e9 synth\u00e9tique. Au fil des d\u00e9cennies, le Dr Ashworth a contribu\u00e9 \u00e0 de nombreux programmes visant \u00e0 traduire les relations de l\u00e9talit\u00e9 synth\u00e9tique en th\u00e9rapies anticanc\u00e9reuses transformatrices.<\/p>\n

\u201cWe\u2019re thrilled to welcome Dr. Ashworth to our Scientific Advisory Board,\u201d said Tomas Babak, Ph.D., Founder and Chief Scientific Officer of Leapfrog Bio. \u201cFew scientists have shaped the clinical application of synthetic lethality as profoundly or demonstrated such a clear understanding of what it takes to translate biology into patient benefit. From discovering the BRCA\u2013PARP synthetic lethality that made PARP inhibitors successful to leading major cancer centers and building therapeutics companies, Alan has tremendously valuable experience that will help guide our own development programs. As was shown with PARP inhibitors, testing the pharmacological effects of the drugs in synergy with genetic perturbations is key to unlocking their potential as genetically targeted agents. Alan\u2019s perspective strengthens our conviction that our pharmacogenetic approach will lead to compelling opportunities in the synthetic lethality arena.\u201d<\/p>\n

Leapfrog applique une approche pharmacog\u00e9n\u00e9tique syst\u00e9matique pour mettre en \u00e9vidence des vuln\u00e9rabilit\u00e9s g\u00e9n\u00e9tiquement d\u00e9finies dans le cancer, en \u00e9tendant le paradigme de la l\u00e9talit\u00e9 synth\u00e9tique \u00e0 de nouveaux cancers \u00e0 fort impact associ\u00e9s \u00e0 des mutations avec perte de fonction.\n\nLe portefeuille de la soci\u00e9t\u00e9 comprend LFB190, un inhibiteur de BET destin\u00e9 au traitement de tumeurs solides associ\u00e9es \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300, ainsi que LFB083, qui cible des cancers associ\u00e9s \u00e0 des mutations du g\u00e8ne PIK3CA. Les deux programmes ont \u00e9t\u00e9 identifi\u00e9s gr\u00e2ce \u00e0 la plateforme exclusive OncoSLX de Leapfrog.<\/p>\n

\u00ab Nos travaux sur la l\u00e9talit\u00e9 synth\u00e9tique entre les mutations BRCA et les inhibiteurs de PARP ont transform\u00e9 notre fa\u00e7on d\u2019aborder le traitement des cancers associ\u00e9s \u00e0 des mutations avec perte de fonction \u00bb, a d\u00e9clar\u00e9 Alan Ashworth, Ph. D., FRS. \u00ab Ce qui me motive particuli\u00e8rement chez Leapfrog Bio, c\u2019est le parall\u00e8le clair entre nos premiers travaux sur les inhibiteurs de PARP et les d\u00e9couvertes de l\u2019entreprise concernant l\u2019inhibition de BET dans les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300, ainsi que l\u2019ensemble de ses travaux en l\u00e9talit\u00e9 synth\u00e9tique.\n\nAvec deux programmes particuli\u00e8rement prometteurs et une plateforme capable d\u2019en g\u00e9n\u00e9rer de nombreux autres, il s\u2019agit d\u2019une occasion exceptionnelle, et je suis ravi de me joindre au conseil consultatif scientifique. \u00bb<\/p>\n

Le Dr Ashworth est actuellement pr\u00e9sident du Helen Diller Family Comprehensive Cancer Center \u00e0 l\u2019University of California, San Francisco, ainsi que vice-pr\u00e9sident principal, services cliniques en oncologie, chez UCSF Health. Il si\u00e8ge au conseil d\u2019administration de CytomX Therapeutics et est cofondateur de Tango Therapeutics, Azkarra Therapeutics et Tiller Therapeutics.\n\nAuparavant, il a \u00e9t\u00e9 chef de la direction de l\u2019Institute of Cancer Research \u00e0 Londres et directeur du Breakthrough Breast Cancer Research Centre. Il est membre \u00e9lu de l\u2019European Molecular Biology Organization, de l\u2019Academy of Medical Sciences, et Fellow de la Royal Society.\n\nLe Dr Ashworth est titulaire d\u2019un doctorat en biochimie de University College London et d\u2019un baccalaur\u00e9at en chimie et biochimie de l\u2019Imperial College London.<\/p>\n

\u00c0 propos de Leapfrog Bio
<\/b>Leapfrog Bio is a clinical-stage precision oncology company accelerating cancer drug development by identifying clinical stage molecules that can be retargeted as precision therapies for cancers with particular loss-of-function (LOF) mutations. The company\u2019s lead program, LFB190, is a Phase 2-ready, first-in-class, oral small-molecule BET inhibitor for solid tumors with EP300 LOF mutations. Leapfrog Bio leverages its proprietary OncoSLX Platform identifies existing small-molecule drugs that can be developed to treat cancers driven by loss-of-function mutations with a high probability of clinical success. Leapfrog Bio is currently seed-funded by leading biotech investor Two Bear Capital. For more information, visit www.leapfrog.bio<\/a><\/span><\/u>.<\/p>\n

Relations avec les investisseurs<\/b>:
Max Gadicke
Precision AQ
maximilian.gadicke@precisionaq.com<\/u><\/a><\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-617","post","type-post","status-publish","format-standard","hentry","category-press_releases"],"yoast_head":"\nAlan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio<\/title>\n<meta name=\"description\" content=\"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio\" \/>\n<meta property=\"og:description\" content=\"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Leapfrog Bio\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:40:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-19T19:21:37+00:00\" \/>\n<meta name=\"author\" content=\"leapfrogbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"leapfrogbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"},\"author\":{\"name\":\"leapfrogbio\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\"},\"headline\":\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board\",\"datePublished\":\"2026-03-24T14:40:11+00:00\",\"dateModified\":\"2026-10-19T19:21:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"},\"wordCount\":865,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\",\"url\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\",\"name\":\"Alan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#website\"},\"datePublished\":\"2026-03-24T14:40:11+00:00\",\"dateModified\":\"2026-10-19T19:21:37+00:00\",\"description\":\"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.leapfrog.bio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.leapfrog.bio\/#website\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"name\":\"Leapfrog Bio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.leapfrog.bio\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\",\"name\":\"Leapfrog Bio\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"contentUrl\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"width\":510,\"height\":90,\"caption\":\"Leapfrog Bio\"},\"image\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\",\"name\":\"leapfrogbio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"caption\":\"leapfrogbio\"},\"sameAs\":[\"https:\/\/www.leapfrog.bio\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio","description":"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","og_locale":"fr_CA","og_type":"article","og_title":"Alan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio","og_description":"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.","og_url":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","og_site_name":"Leapfrog Bio","article_published_time":"2026-03-24T14:40:11+00:00","article_modified_time":"2026-10-19T19:21:37+00:00","author":"leapfrogbio","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"leapfrogbio","Estimation du temps de lecture":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#article","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"},"author":{"name":"leapfrogbio","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3"},"headline":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board","datePublished":"2026-03-24T14:40:11+00:00","dateModified":"2026-10-19T19:21:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"},"wordCount":865,"commentCount":0,"publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"articleSection":["Press Releases"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","url":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","name":"Alan Ashworth Named Scientific Advisory Board Chair - Leapfrog Bio","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/#website"},"datePublished":"2026-03-24T14:40:11+00:00","dateModified":"2026-10-19T19:21:37+00:00","description":"Alan Ashworth, PhD, FRS, of UCSF, co-discoverer of BRCA\u2013PARP synthetic lethality, will chair Leapfrog Bio\u2019s Scientific Advisory Board.","breadcrumb":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.leapfrog.bio\/"},{"@type":"ListItem","position":2,"name":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.leapfrog.bio\/#website","url":"https:\/\/www.leapfrog.bio\/","name":"Leapfrog Bio","description":"","publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.leapfrog.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.leapfrog.bio\/#organization","name":"Leapfrog Bio","url":"https:\/\/www.leapfrog.bio\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/","url":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","contentUrl":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","width":510,"height":90,"caption":"Leapfrog Bio"},"image":{"@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3","name":"leapfrogbio","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","caption":"leapfrogbio"},"sameAs":["https:\/\/www.leapfrog.bio"]}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"leapfrogbio","author_link":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"},"_links":{"self":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/comments?post=617"}],"version-history":[{"count":10,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617\/revisions"}],"predecessor-version":[{"id":684,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617\/revisions\/684"}],"wp:attachment":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/media?parent=617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/categories?post=617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/tags?post=617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}